Management of Multiple Myeloma Patients with Renal Dysfunction

  • Sikander Ailawadhi
  • Chanan-Khan Asher
Part of the Contemporary Hematology book series (CH)


Multiple myeloma (MM) is a systemic disorder with ability to affect multiple organ systems including the renal system. Renal dysfunction is an important complication in patients with MM that can result in a limitation of therapeutic options and is associated with a compromised survival. 1 Among newly diagnosed MM patients, ~50% are noted to have a decrease in creatinine clearance (Cr Cl) while 10% of the patients will require dialysis due to severe renal impairment. 2 The incidence of renal failure in MM patients differs among various reported series depending on the criteria used to define renal failure as well as the patient population studied. Among the MM patients who present with renal dysfunction on initial presentation, at least 20% can be classified as having renal failure defined by an increase ≥2.0 mg/dL (177 micromole/L) in serum creatinine concentrations. 3In a series of 66 MM patients at Roswell Park Cancer Institute we used the National Kidney Foundation's...


Multiple Myeloma Light Chain Renal Dysfunction Overall Response Rate Continuous Ambulatory Peritoneal Dialysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dr. Edit Weber, Department of Pathology, Buffalo General Hospital, Buffalo, N Y.


  1. 1.
    CG W. Acute myeloma kidney. Kidney Int. 1995;48:1347–1361.Google Scholar
  2. 2.
    Torra R BJ, Cases A. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995;91:854–859.PubMedGoogle Scholar
  3. 3.
    Bladé J F-LP, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–1893.Google Scholar
  4. 4.
    K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification; 2000.Google Scholar
  5. 5.
    Bergman LW KW. Co-translational modification of nascent immunoglobulin heavy and light chains. J Supramol Struct. 1979;11:9–24.PubMedGoogle Scholar
  6. 6.
    Endelman GM GJ. The nature of Bence-Jones proteins′' chemical similarities to polypeptide chains of myeloma globulins and normal gamma-globulins. J Exp Med. 1962;116:207–227.Google Scholar
  7. 7.
    Baylis C F-SJ, Ross B. Glomerular and tubular handling of differently charged human immunoglobulin light chains by the rat kidney. Clin Sci. 1988;74:639–644.PubMedGoogle Scholar
  8. 8.
    Sanders PW HG. Monoclonal immunoglobulin light chain-related renal diseases. Semin Nephrol. 1993;13:324–341.PubMedGoogle Scholar
  9. 9.
    Uchida M KK, Okubo M. Renal dysfunction in multiple myeloma. Intern Med. 1995;34:364–370.PubMedGoogle Scholar
  10. 10.
    Rota S MB, Baudouin B, et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore). 1987;66:126–137.Google Scholar
  11. 11.
    Sanders PW BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest. 1992;89:630–639.PubMedGoogle Scholar
  12. 12.
    Cohen DJ SW, Osserman EF, et al. Acute renal failure in patients with multiple myeloma. Am J Med. 1984;76:247–256.PubMedGoogle Scholar
  13. 13.
    Hoitsma AJ WJ, Koene RA. Drug-induced neprotoxicity. Aetiology, clinical features and management. Drug Saf. 1991;6:131–147.PubMedGoogle Scholar
  14. 14.
    Rashed A AB, Abu Romesh SH. Acyclovir-induced acute tubulo-interstitial nephritis. Nephron. 1990;56:436–438.PubMedGoogle Scholar
  15. 15.
    Pozzi C PS, Donini U, et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Clin Nephrol. 1987;27:1–9.Google Scholar
  16. 16.
    Pasquali S Z P, Casanova S, et al. Renal histological lesions and clinical syndromes in multiple myeloma. Renal Immunopathology Group. Clin Nephrol. 1987;27:222–228.PubMedGoogle Scholar
  17. 17.
    B I. Renal complications in multiple myeloma. Acta Morphol Hung. 1989;37:235–243.Google Scholar
  18. 18.
    Montseny JJ KD, Meyrier A, et al. Long-term outcome according to renal his-tological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998;13:1438–1445.PubMedGoogle Scholar
  19. 19.
    PW S. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med. 1994;124:484–488.Google Scholar
  20. 20.
    Leboulleux M LB, Mougenot B, et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int. 1995;48:72–79.PubMedGoogle Scholar
  21. 21.
    Sanders PW HG, Kirk KA, et al. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest. 1991;64:527–537.PubMedGoogle Scholar
  22. 22.
    Pirani CL SF, D′'Agati V, et al. Renal lesions in plasma cell dyscrasias: ultrastructural observations. Am J Kidney Dis. 1987;10:208–221.PubMedGoogle Scholar
  23. 23.
    Smolens P BJ, Kreisberg R Hypercalcemia can potentiate the nephrotoxicity of Bence Jones proteins. J Lab Clin Med. 1987;110:460–465.PubMedGoogle Scholar
  24. 24.
    Holland MD GJ, Sanders PW, et al. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int. 1985;27:46–50.PubMedGoogle Scholar
  25. 25.
    Morgan C Jr HW. Intravenous urography in multiple myeloma. N Engl J Med. 1966;275:77.PubMedGoogle Scholar
  26. 26.
    Sanders PW BB, Bishop JB, et al. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest. 1990;85:570–576.PubMedGoogle Scholar
  27. 27.
    Sanders PW HG, Chen A, et al. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest. 1988;82:2086–2096.PubMedGoogle Scholar
  28. 28.
    Huang ZQ SP. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest. 1997;99:732–736.PubMedGoogle Scholar
  29. 29.
    Melcion C MB, Baudouin B, et al. Renal failure in myeloma: relationship with isoelectric point of immunoglobulin light chains. Clin Nephrol. 1984;22:138–143.PubMedGoogle Scholar
  30. 30.
    Myatt EA WF, Weiss DT, et al. Pathogenic potential of human monoclonal immu-noglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci USA. 1994;91:3034–3038.PubMedGoogle Scholar
  31. 31.
    Decourt C RA, Bridoux F, et al. Mutational analysis in murine models for myeloma-associated Fanconi′'s syndrome or cast myeloma nephropathy. Blood. 1999;94:3559–3566.PubMedGoogle Scholar
  32. 32.
    Solomon A WD, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991;324:1845–1851.PubMedGoogle Scholar
  33. 33.
    Kisilevsky R YI. Pathogenesis of amyloidosis. Baillieres Clin Rheumatol. 1994;8:613–626.PubMedGoogle Scholar
  34. 34.
    Jancelewicz Z TK, Sugai S, et al. IgD multiple myeloma. Arch Intern Med. 1975;135:87–93.PubMedGoogle Scholar
  35. 35.
    Stone MJ FE. The clinical spectrum of light chain myeloma. A study of 35 patients with special reference to the occurrence of amyloidosis. Am J Med. 1975;58:601–619.PubMedGoogle Scholar
  36. 36.
    Bellotti V MG, Bucciarelli E, et al. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol. 1990;74:65–69.PubMedGoogle Scholar
  37. 37.
    Perfetti V CS, Palladini G, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood. 2002;100:948–953.PubMedGoogle Scholar
  38. 38.
    Hurle MR HL, Li L, et al. A role for destabilizing amino acid replacements in light-hain amyloidosis. Proc Natl Acad Sci USA. 1994;91:5446–5450.PubMedGoogle Scholar
  39. 39.
    Buxbaum JN CJ, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med. 1990;112:455–464.PubMedGoogle Scholar
  40. 40.
    Lin J MG, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12:1482–1492.PubMedGoogle Scholar
  41. 41.
    Pozzi C DAM, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42:1154–1163.PubMedGoogle Scholar
  42. 42.
    Noel LH DD, Ganeval D, et al. Renal granular monoclonal light chain deposits: morphological aspects in 11 cases. Clin Nephrol. 1984;21:263–269.PubMedGoogle Scholar
  43. 43.
    Dragsted PJ HN. The association of the Fanconi syndrome with malignant disease. Danish Med Bull. 1956;3:177–179.PubMedGoogle Scholar
  44. 44.
    Headley RN KJ, Cooper MR, et al. Multiple myeloma presenting as adult Fanconi syndrome. Clin Chem. 1972;18:293–295.PubMedGoogle Scholar
  45. 45.
    Lee DB DJ, Rosen VJ, et al. The adult Fanconi syndrome: observations on etiology, morphology, renal function and mineral metabolism in three patients. Medicine (Baltimore). 1972;51:107–138.Google Scholar
  46. 46.
    Aucouturier P BM, Khamlichi AA, et al. Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi'′s syndrome. J Immunol. 1993;150:3561–3568.PubMedGoogle Scholar
  47. 47.
    Orfila C LJ, Modesto A, et al. Fanconi′ 's syndrome, kappa light-chain myeloma, non-amyloid fibrils and cytoplasmic crystals in renal tubular epithelium. Am J Nephrol. 1991;11:345–349.PubMedGoogle Scholar
  48. 48.
    Troung LD, Mawad J CP, et al. Cytoplasmic crystals in multiple myeloma-associated Fanconi′ 's syndrome. A morphological study including immunoelectron microscopy. Arch Pathol Lab Med. 1989;113:781–785.Google Scholar
  49. 49.
    Kambham N MG, Appel GB, et al. Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis. 1999;33:954–962.PubMedGoogle Scholar
  50. 50.
    Aucouturier P KA, Touchard G et al. Heavy-chain deposition disease. N Engl J Med. 1993;329:1389–1393.PubMedGoogle Scholar
  51. 51.
    Liapis H PI, Nakopoulou L. Nodular glomerulosclerosis secondary to mu heavy chain deposits. Human Pathol. 2000;31:122–125.Google Scholar
  52. 52.
    Vedder AC WJ, Krediet RT. Intracapillary proliferative glomerulonephritis due to heavy chain deposition disease. Nephrol Dial Transplant. 2004;19:1302–1304.PubMedGoogle Scholar
  53. 53.
    Geneval D CM, Noel L-H, et al. Kidney involvement in multiple myeloma and related disorders. Contrib Nephrol. 1982;33:210–222.Google Scholar
  54. 54.
    Hill GS M-ML, Mery JP, et al. Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. Am J Kidney Dis. 1983;2:423–438.PubMedGoogle Scholar
  55. 55.
    Choukroun G VB, Grunfeld J-P. Multiple myeloma. Part I: Renal renal involvement. Clin Issues Nephrol. 1995;70:11–17.Google Scholar
  56. 56.
    Burke JR Jr FR, Lasker N, et al. Malignant lymphoma with ″“myeloma kidney″” acute renal failure. Am J Med. 1976;60:1055–1060.PubMedGoogle Scholar
  57. 57.
    Isaac J HG. Cast nephropathy in a case of Waldenstrom′'s macroglobulinemia. Nephron. 2002;91:512–515.PubMedGoogle Scholar
  58. 58.
    Soffer O NV, Campbell WG Jr, et al. Light chain cast nephropathy and acute renal failure associated with rifampin therapy. Renal disease akin to myeloma kidney. Am J Med. 1987;82:1052–1056.PubMedGoogle Scholar
  59. 59.
    Doe WF DF, Seligmann M. Immunodiagnosis of alpha chain disease. Clin Exp Immunol. 1979;36:189–197.PubMedGoogle Scholar
  60. 60.
    Levi DF WR, Lindstrom FD. Immunofluorescent studies of the myeloma kidney with special reference to light chain disease. Am J Med. 1968;44:922–933.PubMedGoogle Scholar
  61. 61.
    Johnson WJ KR, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma: plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990;150:863–869.PubMedGoogle Scholar
  62. 62.
    Pasquali S CS, Zucchelli P, et al. Long-term survival in patients with acute and severe renal failure due to multiple myeloma. Clin Nephrol. 1990;34:247–254.PubMedGoogle Scholar
  63. 63.
    Geneval D RC, Guerin V, et al. Treatment of multipe myeloma with renal involvement. Adv Nephrol. 1992;21:347–370.Google Scholar
  64. 64.
    Misiani R TG, Mingardi G, et al. Management of myeloma kidney: an anti-light-chain approach. Am J Kidney Dis. 1987;10:28–33.PubMedGoogle Scholar
  65. 65.
    Iggo N WC, Davies ER. The development of cast nephropathy in multiple myeloma. QJM. 1997;90.Google Scholar
  66. 66.
    Feest TG BP, Cohen SL. Successful treatment of myeloma kidney by diuresis and plasmapheresis. BMJ. 1976;i:503–507.Google Scholar
  67. 67.
    Misiani R RG, Bertani T, et al. Plasmapheresis in the treatment of acute renal failure in multiple myeloma. Am J Med. 1979;66:684–688.PubMedGoogle Scholar
  68. 68.
    Locatelli F PC, Pedrini L, et al. Steroid pulses and plasmapheresis in the treatment of acute renal failure in multiple myeloma. Proc EDTA. 1980;17:690–694.Google Scholar
  69. 69.
    Zucchelli P PS, Cagnoli L, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988;33:1175–1180.PubMedGoogle Scholar
  70. 70.
    Rosansky SJ RF. Use of peritoneal dialysis in the treatment of patients with renal failure and paraproteinemia. Am J Nephrol. 1985;5:361–365.PubMedGoogle Scholar
  71. 71.
    Solling K SJ. Clearance of Bence-Jones proteins during peritoneal dialysis or plasmapheresis in myelomatosis associated with renal failure. Contrib Nephrol. 1988;68:259–262.PubMedGoogle Scholar
  72. 72.
    Iggo N PA, Severn A, et al. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwile treatment. QJM. 1989;73:903–910.PubMedGoogle Scholar
  73. 73.
    Shetty A OD. Myeloma patients do well on CAPD too! Br J Haematol. 1997;96:654–657.PubMedGoogle Scholar
  74. 74.
    Cosio FG PT, Shapiro FL, et al. Severe renal failure in multiple myeloma. Clin Nephrol. 1981;15:206–210.PubMedGoogle Scholar
  75. 75.
    DE B. The role of chemotherapy in the treatment of multiple myeloma. Bailliere′'s Clin Haematol. 1995;8:783–794.Google Scholar
  76. 76.
    Walker F BR. Renal transplantation in light-chain multiple myeloma. Am J Nephrol. 1983;3:34–37.PubMedGoogle Scholar
  77. 77.
    Humphrey RL WJ, Zachary JB, et al. Renal transplantation in multiple myeloma. Ann Intern Med. 1975;83:651–653.PubMedGoogle Scholar
  78. 78.
    Sammett D DF, abbi R, et al. Renal transplantation in multiple myeloma: case report and review of literature. Transplantation. 1996;62:1577–1580.PubMedGoogle Scholar
  79. 79.
    Passweg J BH, Tichelli A, et al. Transient multiple myeloma after intense immunosup-pression in a renal transplant patient. Nephrol Dial Transplant. 1993;8:1393–1394.PubMedGoogle Scholar
  80. 80.
    Gerlag PGG KR, Berden JHM. Renal transplantation in light chain nephropathy: case report and review of the literature. Clin Nephrol. 1986;25:101–104.PubMedGoogle Scholar
  81. 81.
    Scully RE GJ, McNeely BU. Case records of the Massachusetts General Hospital: case 1–1981. N Engl J Med. 1981;304:33–43.Google Scholar
  82. 82.
    Knudsen LM HM, Hippe E. Renal failure in multiple myeloma: reversibility and impact on prognosis. Eur J Haematol. 2000;65:175–181.PubMedGoogle Scholar
  83. 83.
    Korzets A TF, Russell G, et al. The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis. 1990;6:216–223.Google Scholar
  84. 84.
    Medical Research Council Working Party on Leukemia in Adults. Analysis and management of renal failure in the fourth myelomatosis trial. Br Med J. 1984;288:1411–1416.Google Scholar
  85. 85.
    Barlogie B SL, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353–1356.PubMedGoogle Scholar
  86. 86.
    Aitchison RG RI, Morgan AG, et al. Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure. Br J Cancer. 1990;61:765–766.PubMedGoogle Scholar
  87. 87.
    Ballester OF TR, Janssen WE, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal failure. Bone Marrow Transplant. 1997;20:653–656.PubMedGoogle Scholar
  88. 88.
    Rebibou JM CD, Cassanovas RO, et al. Peripheral blood stem cell transplantation in a myeloma patient with end-stage renal failure. Bone Marrow Transplant. 1997;20:63–65.PubMedGoogle Scholar
  89. 89.
    Reiter E K P, Keil F, et al. Effects of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Ann Hematol. 1999;78:189–191.PubMedGoogle Scholar
  90. 90.
    Tosi F ZE, Ronconi S, et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia. 2000;14:1310–1313.PubMedGoogle Scholar
  91. 91.
    San Miguel JF LJ, Gar ia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematologica. 2000;1:28–36.Google Scholar
  92. 92.
    Badros A BB, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600–607.PubMedGoogle Scholar
  93. 93.
    Tosi P ZE, Cellini C, et al. Thalidomide alone or in combination with dexametha-sone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73:98–103.PubMedGoogle Scholar
  94. 94.
    Pineda-Roman M TG. High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol. 2007;153:182–194.PubMedGoogle Scholar
  95. 95.
    Harris E BJ, Samson D, et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol. 2003;122:160–161.PubMedGoogle Scholar
  96. 96.
    Eriksson T HP, Turesson I, et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol. 2003;55:1701–1706.PubMedGoogle Scholar
  97. 97.
    Revlimid® (lenalidomide);: package Package insert.: Celgene Corporation; 2006.Google Scholar
  98. 98.
    Jagannath S BB, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma; initial clinical experience in patients with impaired renal function. Cancer. 2005;103:1195–1200.PubMedGoogle Scholar
  99. 99.
    Chanan-Khan AA KJ, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604–2606.PubMedGoogle Scholar
  100. 100.
    Kastritis E AA, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Hematologica. 2007;92:546–549.Google Scholar
  101. 101.
    Croucher PI AJ. Bone disease in multiple myeloma. Br J Haematol. 1998;103: 902–910.PubMedGoogle Scholar
  102. 102.
    Rodan GA FH. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692–2696.PubMedGoogle Scholar
  103. 103.
    Sato M GW, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88:2095–2105.PubMedGoogle Scholar
  104. 104.
    H F. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80–100.Google Scholar
  105. 105.
    Owens JM FK, Chambers TJ. Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J Cell Physiol. 1997;172:79–86.PubMedGoogle Scholar
  106. 106.
    Reszka AA H-NJ, Masarachia PJ, et al. Bisphosphonates act directly on the osteo-clast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem. 1999;274:34967–34973.PubMedGoogle Scholar
  107. 107.
    Berenson JR HB, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719–3736.PubMedGoogle Scholar
  108. 108.
    Zometa (zoledronic acid): Prescribing information.: Novartis Pharmaceuticals Corporation; 2007.Google Scholar
  109. 109.
    Aredia (pamidronate): Prescribing information.: Novartis Pharmaceuticals Corporation; 2007.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sikander Ailawadhi
    • 1
  • Chanan-Khan Asher
    • 1
  1. 1.Department of MedicineRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations